2009-11-16 02:35:20 - CombinatoRx, Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com

www.companiesandmarkets.com/Summary-Company-Profile/combinatorx, ..

CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. It also has a

 

 

pipeline of preclinical product candidates in development. More from Reuters »

CombinatoRx, Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company engaged in developing synergistic combinations pharmaceuticals. The company currently has a portfolio of products in the 2nd phase clinical trials associated with the treatment of rheumatoid arthritis, psoriasis, atopic dermatitis, Type-2 diabetes and asthma. The company is headquartered in Cambridge, United States

The CombinatoRx, Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick ""one-stop-shop"" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.